Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1–risk myelodysplastic syndrome and thrombocytopenia

BACKGROUND: Thrombocytopenia in patients with myelodysplastic syndrome (MDS) is associated with shortened survival and an increased risk of evolution to acute myeloid leukemia (AML). In this study, the authors evaluated the efficacy of romiplostim in patients who had thrombocytopenia with low-risk/i...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer
Autori principali: Giagounidis, Aristoteles, Mufti, Ghulam J, Fenaux, Pierre, Sekeres, Mikkael A, Szer, Jeffrey, Platzbecker, Uwe, Kuendgen, Andrea, Gaidano, Gianluca, Wiktor-Jedrzejczak, Wieslaw, Hu, Kuolung, Woodard, Paul, Yang, Allen S, Kantarjian, Hagop M
Natura: Artigo
Lingua:Inglês
Pubblicazione: BlackWell Publishing Ltd 2014
Soggetti:
Original Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4298760/
https://ncbi.nlm.nih.gov/pubmed/24706489
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.28663
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi